PCN136 Cost-Effectiveness Analysis of Dacomitinib Versus Gefitinib for the First-line Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR)-Activating Mutations in Portugal
Dec 1, 2020, 00:00
10.1016/j.jval.2020.08.273
https://www.valueinhealthjournal.com/article/S1098-3015(20)32529-8/fulltext
Title :
PCN136 Cost-Effectiveness Analysis of Dacomitinib Versus Gefitinib for the First-line Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR)-Activating Mutations in Portugal
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)32529-8&doi=10.1016/j.jval.2020.08.273
First page :
Section Title :
Open access? :
No
Section Order :
10217